Gastroenterology | Preclinical Developments

Alivio Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense

Lead Product(s): ALV-304

Therapeutic Area: Gastroenterology Product Name: ALV-304

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: U.S. Department of Defense

Deal Size: $3.3 million Upfront Cash: Undisclosed

Deal Type: Funding October 05, 2020

Details:

The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.

Rodeo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease

Lead Product(s): RTX-1688

Therapeutic Area: Gastroenterology Product Name: RTX-1688

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2020

Details:

Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings .

Prometheus Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody

Lead Product(s): PR600

Therapeutic Area: Gastroenterology Product Name: PR600

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Dr. Falk Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 13, 2020

Details:

Under the terms of the agreement, Prometheus and Falk will share responsibility for the global development of PR600, with Falk contributing one-quarter of the costs associated with developing PR600.

Morphic Therapeutic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease

Lead Product(s): MORF-057

Therapeutic Area: Gastroenterology Product Name: MORF-057

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

The data presented at DDW demonstrate that MORF-057 successfully targets the integrin α4β7 with high potency and selectivity.

Synlogic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Synlogic Announces Termination of AbbVie Collaboration Agreement

Lead Product(s): Synthetic Biotic medicines

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 21, 2020

Details:

Upon termination, Synlogic regains all rights to develop Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).

Morphic Therapeutic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin

Lead Product(s): MORF-057

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2020

Details:

Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

Alpine Immune Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chr...

Lead Product(s): ALPN-101

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.